Abstract
BackgroundDiffuse intrinsic pontine glioma (DIPG) is the most common brainstem cancer in childhood. This rapidly progressing brainstem glioma holds a very dismal prognosis with median survival of less than 1 year. Despite extensive research, no significant therapeutic advancements have been made to improve overall survival in DIPG patients.MethodsHere, we used an orthotopic xenograft pediatric DIPG (HSJD-DIPG-007) mouse model to monitor the effects of anti-cancer agent, OKlahoma Nitrone-007 (OKN-007), as an inhibitor of tumor growth after 28 days of treatment. Using magnetic resonance imaging (MRI), we confirmed the previously described efficacy of LDN-193189, a known activin A receptor, type I (ACVR1) inhibitor, in decreasing tumor burden and found that OKN-007 was equally efficacious.ResultsAfter 28 days of treatment, the tumor volumes were significantly decreased in OKN-007 treated mice (p < 0.01). The apparent diffusion coefficient (ADC), as a measure of tissue structural alterations, was significantly decreased in OKN-007 treated tumor-bearing mice (p < 0.0001). Histological analysis also showed a significant decrease in CD34 expression, essential for angiogenesis, of OKN-007 treated mice (p < 0.05) compared to LDN-193189 treated mice. OKN-007-treated mice also significantly decreased protein expression of the human nuclear antigen (HNA) (p < 0.001), ACVR1 (p < 0.0001), and c-MET (p < 0.05), as well as significantly increased expression of cleaved caspase 3 (p < 0.001) and histone H3 K27-trimethylation (p < 0.01), compared to untreated mouse tumors.ConclusionsWith the dismal prognosis and limited effective chemotherapy available for DIPG, there is significant room for continued research studies, and OKN-007 merits further exploration as a therapeutic agent.
Highlights
Diffuse intrinsic pontine glioma (DIPG) is the most common brainstem cancer in childhood
In addition to OKlahoma Nitrone-007 (OKN-007), we evaluated the efficacy of a known Activin A receptor (ACVR1) inhibitor, LDN-193189
The Diffusion-weighted imaging (DWI) on day 57, prior to termination, showed that the untreated mice had significantly higher (p value < 0.001) normalized apparent diffusion coefficient (ADC) values compared to the normalized ADC values of both treatment groups, OKN-007 and LDN-193189 (Fig. 3)
Summary
Diffuse intrinsic pontine glioma (DIPG) is the most common brainstem cancer in childhood. This rapidly progressing brainstem glioma holds a very dismal prognosis with median survival of less than 1 year. DIPG usually has been a diagnosis made by magnetic resonance imaging (MRI) findings alone. This is a great area of change as large clinical centers are obtaining tissue biopsy at the time of diagnosis to better unravel the true biology of DIPG. H3.1-K27M is usually a co-mutation with ACVR1 mutations, which is the second most common mutation in DIPG, with approximately 25% of cases harboring this mutation [5] These mutations contribute to the aggressive biology and poor treatment response. DIPG has had no significant improvement in overall survival, and there is clearly a dire need for therapeutic advancements [2]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.